Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden
Cancer Medicine · 2024-04 · 13 (8)
DOI: 10.1002/cam4.7048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.04.2024. Verfasst von Katarina Uttervall und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Antibodies, Bispecific. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T‐cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results This study evaluated the efficacy and safety of BCMA T‐cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression‐free survival at 15 months.
Conclusions
Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real‐world data highlight the potential of BCMA T‐cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Haematology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Department of Hematology, Lund University, Lund, Sweden.
- Department of Medicine, Orebro University Hospital, Orebro, Sweden.
- Section of Hematology Department of Internal Medicine, Hallands Sjukhus Varberg, Varberg, Sweden.
- Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID-Profile: Katarina Uttervall, Love Tätting
Zitieren
APA
Uttervall, K., Tätting, L., Lemonakis, K., Majd, M., Crafoord, J., Olsson, M., Mellqvist, U. H., Hansson, M., & Nahi, H. (2024). Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden. Cancer Medicine, 13(8). https://doi.org/10.1002/cam4.7048
Vancouver
Uttervall K, Tätting L, Lemonakis K, Majd M, Crafoord J, Olsson M, et al. Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden. Cancer Medicine. 2024;13(8). doi:10.1002/cam4.7048
BibTeX
@article{Uttervall2024,
author = {Uttervall, Katarina and Tätting, Love and Lemonakis, Konstantinos and Majd, Mousa and Crafoord, Jacob and Olsson, Mikael and Mellqvist, Ulf-Henrik and Hansson, Markus and Nahi, Hareth},
title = {Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {8},
doi = {10.1002/cam4.7048}
}
EUVIMED